甲磺酸去铁胺.|138-14-7|(甲磺酸去铁胺; Desferrioxamine B mesylate; DFOM)-陌孚医药/Medlife

您当前的位置：

甲磺酸去铁胺. (Synonyms: 甲磺酸去铁胺; Desferrioxamine B mesylate; DFOM)

目录号: PC15129 纯度: ≥98%

CAS No. :138-14-7

商品编号	规格	价格	会员价	是否有货	数量
PC15129-100mg	100mg	¥519.40	请登录
PC15129-500mg	500mg	¥882.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	甲磺酸去铁胺.
中文别名	甲磺酸去铁胺;甲磺酸去铁敏;甲磺酸除铁灵;甲磺酸去铁胺标准品;甲磺酸去铁胺标准品(JP);去铁铵;去铁铵 USP标准品;去铁胺甲磺酸盐 EP标准品;去铁胺甲磺酸酯;十一酸甘油三酯;云铁胺甲磺酸酯;DEFEROX胺甲磺酸盐;去铁胺甲磺酸盐;去铁铵/去铁敏
英文名称	Deferoxamine mesylate
英文别名	Deferoxamine mesylate;Deferoxamine mesylate salt;Deferoxamine (mesylate);EHNA;Deferoxamine Methanesulfonate;Desferrioxamine B mesylate;DFOM;DFOM,Deferoxamine methanesulfonate salt,Desferrioxamine mesylate salt;Deferoxamine methanesulfonate salt;Desferrioxamine mesylate salt;desferal;Prestwick_988;desferalmesylate;deferoxaminemesilate;deferoxaminebmesylate;DEFEROXAMINE MESYLATE;monomethanesulfonate(sa;desferrioxaminebmesylate;desferalmethanesulfonate
Cas No.	138-14-7
分子式	C₂₇H₅₆N₆O₁₄S₂
分子量	752.90
包装储存	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

生物活性

Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.

性状

Solid

体外研究(In Vitro)

Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells.
Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels.
Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs.
Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs.
Deferoxamine mesylate (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs.
Deferoxamine mesylate (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	MEFs cells
Concentration:	1 mM
Incubation Time:	16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
Result:	Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions. Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

Western Blot Analysis

Cell Line:	HepG2 cells
Concentration:	100 μM
Incubation Time:	24 h
Result:	Showed a twofold increase of InsR mRNA levels in cells. Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.

Cell Proliferation Assay

Cell Line:	TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))
Concentration:	5, 10, 25, 50, 100 μM
Incubation Time:	7 days (TAMSCs); 9 days (BMMSCs)
Result:	Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 μM dose.

Apoptosis Analysis

Cell Line:	TAMSCs, BMMSCs
Concentration:	5, 10, 25, 50, 100 μM
Incubation Time:	7 days
Result:	Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.

Western Blot Analysis

Cell Line:	TAMSCs, BMMSCs
Concentration:	10 μM
Incubation Time:	3 days
Result:	Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.

Cell Autophagy Assay

Cell Line:	SH-SY5Y cells
Concentration:	100 μM
Incubation Time:	24 h
Result:	Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection. Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.

体内研究(In Vivo)

Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice.
Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model).
Dosage:	560.68 mg/per (10 uL of 1 mM)
Administration:	Drip-on; once daily for 21 days.
Result:	Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.

Animal Model:	Male Sprague-Dawley rats (180-200 g).
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection; daily for 2 weeks.
Result:	Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.

运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ClinicalTrial

参考文献

[1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e. [Information]

[2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47. [Information]

[3]. Wang G, et al. 体外研究 assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. [Information]

[4]. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205. [Information]

[5]. Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26(11):3255. [Information]

溶解度数据

体外研究:

H₂O : 250 mg/mL (380.64 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5226 mL	7.6128 mL	15.2256 mL
5 mM	0.3045 mL	1.5226 mL	3.0451 mL
10 mM	0.1523 mL	0.7613 mL	1.5226 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 5.56 mg/mL (8.47 mM); Clear solution; Need ultrasonic

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation